23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
1. 23andMe is exploring a sale of its telehealth business, Lemonaid. 2. Company's stock price has significantly declined since the 2023 data breach. 3. 23andMe's valuation fell from $3.5 billion in 2021 to $91 million now. 4. Settlement of a $30 million class-action lawsuit reduced financial stability. 5. CEO Anne Wojcicki's private buyout attempts have faced board resistance.